摘要
fezolinetant(商品名:Veozah^(TM))是美国FDA批准的第1款用于治疗围绝经期血管舒缩症状(vasomotor symptoms,VMS)的选择性神经激肽3受体(neurokinin 3 receptor,NK3R)拮抗剂。与传统的雌激素疗法相比,fezolinetant降低了心血管不良事件及乳腺癌的发生风险。临床研究证实,fezolinetant可显著降低中重度VMS的发生频率与严重程度,且安全性良好。本文就fezolinetant的作用机制、药动学、药效学、临床疗效、安全性、药物相互作用等方面进行介绍。
Fezolinetant(tradename:Veozah^(TM))is the first FDA-approved selective neurokinin 3 receptor(NK3R)antagonist for the treatment of perimenopausal vasomotor symptoms(VMS).Compared with traditional hormone therapy,fezolinetant reduced the risk of cardiovascular adverse events and breast cancer.Clinical studies have demonstrated that fezolinetant can significantly reduce the frequency and severity of moderate-to-severe VMS with good safety.In this article,the mechanism of action,pharmacokinetics,pharmacodynamics,clinical evaluation,safety,and drug interactions of fezolinetant are reviewed.
作者
肖然
杜小莉
XIAO Ran;DU Xiao-li(Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2024年第8期752-755,共4页
Chinese Journal of New Drugs
